Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Elsa Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing
PENTIXAPHARM Secures € 15 Million Series A Financing
Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
June 02, 2020
Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Elsa Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing